Entries |
Document | Title | Date |
20080207588 | Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines - The present invention is concerned with certain novel derivatives of Formula I, | 08-28-2008 |
20090018113 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof - The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation. | 01-15-2009 |
20090018114 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to cannabinoid receptor ligands containing compounds of formula (I) | 01-15-2009 |
20090054396 | SUBSTITUTED THIOPHENES AND USES THEREOF - This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer. | 02-26-2009 |
20090093453 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF - Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof: | 04-09-2009 |
20090186868 | Taxane Compound Having Azetidine Ring Structure - A compound represented by the general formula (1) [X | 07-23-2009 |
20090209512 | NEUROGENESIS INDUCER OR NEUROPATHY THERAPEUTIC AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF - Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof: | 08-20-2009 |
20090247503 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF - Provided herein are 5-demethoxyfumagillol and its derivatives. Also provided herein are methods of making the 5-demethoxyfumagillol and derivatives. Also provided herein are biological activities of the 5-demethoxyfumagillol and derivatives and methods of using same for treating diseases. | 10-01-2009 |
20090325925 | Thiophenes and uses thereof - This invention provides thiophene compounds of formula I: | 12-31-2009 |
20100056490 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors - The invention relates to novel heterocyclic compounds of the formula | 03-04-2010 |
20100099661 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 04-22-2010 |
20100160289 | SULFONAMIDES AS TRPM8 MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) and Formula (II) as follows: | 06-24-2010 |
20100249097 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS - The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments. | 09-30-2010 |
20100286118 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 - The present invention provides compounds of formula (I) | 11-11-2010 |
20110015174 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER - A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. | 01-20-2011 |
20110053908 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME - This disclosure relates to compounds of formula (I): | 03-03-2011 |
20110105461 | MODULATORS OF DOPAMINE NEUROTRANSMISSION - The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 05-05-2011 |
20110105462 | MODULATORS OF DOPAMINE NEUROTRANSMISSION - The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 05-05-2011 |
20110105463 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES - Compounds of Formula (I): in which A | 05-05-2011 |
20110112065 | MODULATORS OF DOPAMINE NEUROTRANSMISSION - The present invention relates to novel 1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 05-12-2011 |
20110112066 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF - An alkyl ether derivative represented by the following general formula [1] | 05-12-2011 |
20110183961 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF - The invention relates to compounds of the formula (I) where: R is a (C | 07-28-2011 |
20110245228 | PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF - Disclosed is a protein kinase C enhancer characterized by containing a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof. | 10-06-2011 |
20120040956 | INHIBITORS OF HIF-1 PROTEIN ACCUMULATION - The invention relates to cyclopentabenzofuran derivatives for the treatment and/or prophylaxis of angiogenesis-related disorders. | 02-16-2012 |
20120165308 | USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS - The present invention provides compounds of the formula (I) | 06-28-2012 |
20120232053 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of the formula: | 09-13-2012 |
20120238541 | PHARMACEUTICAL COMPOUNDS - The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer. | 09-20-2012 |
20120245141 | ACTIVATORS OF HUMAN PYRUVATE KINASE - Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R | 09-27-2012 |
20120258949 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS - This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C | 10-11-2012 |
20120264736 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS - This invention discloses novel gamma secretase inhibitors of the formula: | 10-18-2012 |
20120302546 | NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF - Pharmaceutical compositions of the invention include sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity. | 11-29-2012 |
20120322786 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): | 12-20-2012 |
20120322787 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - A compound is represented by Structural Formula (I): | 12-20-2012 |
20120329775 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 - The present invention provides compounds of formula (I) | 12-27-2012 |
20130053364 | Sulphone Compounds and Methods of Making and Using Same - The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 02-28-2013 |
20130116232 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 05-09-2013 |
20130123235 | Tricyclic Compounds and Methods of Making and Using Same - The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 05-16-2013 |
20130252937 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - The present invention relates to compounds of general formula I, | 09-26-2013 |
20130317000 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula: | 11-28-2013 |
20130317001 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula: | 11-28-2013 |
20130345195 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 12-26-2013 |
20140051678 | INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES - The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and/or preventing cancers presenting tumor-initiating cells. (Formula I) (I) | 02-20-2014 |
20140073627 | BRADYKININ B1 ANTAGONISTS - The invention relates to compounds of formula (I) | 03-13-2014 |
20140088077 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS - The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments. | 03-27-2014 |
20140088078 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same - The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 03-27-2014 |
20140088079 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS - The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound. | 03-27-2014 |
20140107095 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 04-17-2014 |
20140221342 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES - Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I | 08-07-2014 |
20140256702 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 09-11-2014 |
20140275020 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds of Formula I having the following general structure: | 09-18-2014 |
20140336174 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease - A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor. | 11-13-2014 |
20140349991 | CHROMONE DERIVATIVE HAVING OSTEOGENESIS PROMOTING EFFECT - Compounds or pharmacologically acceptable salts thereof for promoting osteogenesis, improving bone metabolism, preventing or treating bone fracture, preventing or treating a disease associated with bone metabolism, or in the field of orthopedics for the promotion of healing of bone fracture, a bone defect, and bone diseases such as osteoarthritis as well as in the field of dentistry for the treatment of periodontal disease and the stabilization of artificial tooth root. The compounds are represented by formula (I) or a pharmacologically acceptable salt thereof: | 11-27-2014 |
20150045345 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)ETHOXY)PROPYL)AZETIDIN-3-OL OR SALT THEREOF - This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof. | 02-12-2015 |
20150080369 | NOVEL COMPOUNDS - The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ. | 03-19-2015 |
20150299115 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL). | 10-22-2015 |
20150361065 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS - The present invention relates to compounds of formula I: in which n, m, X, Y | 12-17-2015 |
20160051531 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 02-25-2016 |
20160102071 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES - Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: | 04-14-2016 |
20160137659 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS - The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. | 05-19-2016 |